Smith J 2nd, Irwin A, Jensen L, Tedesco K, et al. Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer. Clin Breast Cancer 2019 Oct 14. pii: S1526-8209(19)30714.
PMID: 31980406